These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 39339938)

  • 1. Comparative Effects of Efavirenz and Dolutegravir on Metabolomic and Inflammatory Profiles, and Platelet Activation of People Living with HIV: A Pilot Study.
    Roux CG; Mason S; du Toit LDV; Nel JG; Rossouw TM; Steel HC
    Viruses; 2024 Sep; 16(9):. PubMed ID: 39339938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.
    Dugdale CM; Ciaranello AL; Bekker LG; Stern ME; Myer L; Wood R; Sax PE; Abrams EJ; Freedberg KA; Walensky RP
    Ann Intern Med; 2019 May; 170(9):614-625. PubMed ID: 30934067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa (CONNECT): a prospective cohort study.
    Nightingale S; Dreyer AJ; Thomas KGF; van Zyl G; Decloedt E; Naude PJW; Orrell C; Sinxadi P; Winston A; Khoo S; Joska JA
    Lancet HIV; 2024 Oct; 11(10):e680-e689. PubMed ID: 39284338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study.
    Sawry S; Ayalew K; Maimela G; Briggs-Hagen M; van Wyk-Heath M; Mthethwa S; Shai S; Mngomezulu NN; Tlhowe L; Achere-Darko J; Bedford J; Martin CE; Fairlie L; Imrie J
    HIV Med; 2024 Jul; 25(7):826-839. PubMed ID: 38520085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study.
    Shamu T; Egger M; Mudzviti T; Chimbetete C; Manasa J; Anderegg N
    PLoS One; 2024; 19(2):e0293162. PubMed ID: 38394297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viral load non-suppression status among women exposed to Dolutegravir-based versus Efavirenz-based regimens in Ethiopia: A before-and-after study.
    Facha W; Tadesse T; Wolka E; Astatkie A
    PLoS One; 2024; 19(6):e0305331. PubMed ID: 38857273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Point-of-Care Detection of Nonadherence to Antiretroviral Treatment for HIV-1 in Resource-Limited Settings Using Drug Level Testing for Efavirenz, Lopinavir, and Dolutegravir: A Validation and Pharmacokinetic Simulation Study.
    Hermans LE; Nijhuis M; Tempelman HA; Houts T; Schuurman R; Burger DM; Wensing AMJ; ter Heine R
    J Acquir Immune Defic Syndr; 2021 Aug; 87(4):1072-1078. PubMed ID: 34153013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda.
    Twimukye A; Laker M; Odongpiny EAL; Ajok F; Onen H; Kalule I; Kajubi P; Seden K; Owarwo N; Kiragga A; Armstrong-Hough M; Katahoire A; Mujugira A; Lamorde M; Castelnuovo B
    BMC Infect Dis; 2021 Nov; 21(1):1154. PubMed ID: 34774018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attrition from care and its predictors among women exposed to dolutegravir- and efavirenz-based first-line antiretroviral therapy in Ethiopia: a before-and-after study.
    Facha W; Tadesse T; Wolka E; Astatkie A
    Front Public Health; 2024; 12():1385441. PubMed ID: 39015389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.
    Davey S; Ajibola G; Maswabi K; Sakoi M; Bennett K; Hughes MD; Isaacson A; Diseko M; Zash R; Batlang O; Moyo S; Lockman S; Lichterfeld M; Kuritzkes DR; Makhema J; Shapiro R
    J Acquir Immune Defic Syndr; 2020 Jul; 84(3):235-241. PubMed ID: 32195745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety of a dolutegravir (DTG)-based antiretroviral treatment (ART) regimen for pregnancy and birth outcomes in Ethiopia: evidence from multicenter cohort study.
    Gedefaw A; Tadesse BT; Berhan Y; Makonnen E; Vella S; Aklillu E
    BMC Infect Dis; 2024 Sep; 24(1):901. PubMed ID: 39223552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body weight and blood pressure changes on dolutegravir-, efavirenz- or atazanavir-based antiretroviral therapy in Zimbabwe: a longitudinal study.
    Shamu T; Egger M; Mudzviti T; Chimbetete C; Manasa J; Anderegg N
    J Int AIDS Soc; 2024 Feb; 27(2):e26216. PubMed ID: 38332525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and Safety of Dolutegravir Versus Efavirenz-Based Antiviral Regimen in People Living With HIV-1 in Sichuan Province of China: A Real-World Study.
    Tongtong Y; Shenghua H; Yin W; Lin C; Huanxia L; Chunrong L; Ruifeng Z; Xiaojing Y; Yuan Y; Yuanhong H; Ke Y
    J Acquir Immune Defic Syndr; 2022 Oct; 91(S1):S1-S7. PubMed ID: 36094508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically Relevant Concentrations of Dolutegravir, Emtricitabine, and Efavirenz Induce Distinct Metabolic Alterations in HeLa Epithelial and BV2 Microglial Cells.
    George JW; Mattingly JE; Roland NJ; Small CM; Lamberty BG; Fox HS; Stauch KL
    Front Immunol; 2021; 12():639378. PubMed ID: 34093527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.
    Kintu K; Malaba TR; Nakibuka J; Papamichael C; Colbers A; Byrne K; Seden K; Hodel EM; Chen T; Twimukye A; Byamugisha J; Reynolds H; Watson V; Burger D; Wang D; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S;
    Lancet HIV; 2020 May; 7(5):e332-e339. PubMed ID: 32386721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
    Waitt C; Orrell C; Walimbwa S; Singh Y; Kintu K; Simmons B; Kaboggoza J; Sihlangu M; Coombs JA; Malaba T; Byamugisha J; Amara A; Gini J; Else L; Heiburg C; Hodel EM; Reynolds H; Mehta U; Byakika-Kibwika P; Hill A; Myer L; Lamorde M; Khoo S
    PLoS Med; 2019 Sep; 16(9):e1002895. PubMed ID: 31539371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viremia and HIV Drug Resistance Among People Receiving Dolutegravir Versus Efavirenz-Based First-Line Antiretroviral Therapy.
    Dorward J; Sookrajh Y; Lessells R; Bulo E; Bodley N; Singh L; Moodley P; Samsunder N; Drain PK; Hayward G; Butler CC; Garrett N
    J Acquir Immune Defic Syndr; 2024 Apr; 95(5):e8-e11. PubMed ID: 38489494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tryptophan metabolism and its relationship with central nervous system toxicity in people living with HIV switching from efavirenz to dolutegravir.
    Keegan MR; Winston A; Higgs C; Fuchs D; Boasso A; Nelson M
    J Neurovirol; 2019 Feb; 25(1):85-90. PubMed ID: 30478800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
    Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
    Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.